Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
47 hedge funds and large institutions have $23M invested in Clearside Biomedical in 2019 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 6 closing their positions.
423% more capital invested
Capital invested by funds: $4.41M → $23M (+$18.6M)
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
38% more funds holding
Funds holding: 34 → 47 (+13)
0.05% more ownership
Funds ownership: 1.23% → 1.29% (+0.05%)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
86% less call options, than puts
Call options by funds: $254K | Put options by funds: $1.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$434K |
| 2 |
BlackRock
New York
|
+$251K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$213K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$185K |
| 5 |
Renaissance Technologies
New York
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
S
SignatureFD
Atlanta,
Georgia
|
-$176K |
| 2 |
PA
Parallel Advisors
San Francisco,
California
|
-$85.6K |
| 3 |
Millennium Management
New York
|
-$41.3K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$34.3K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$29K |
CLSD Hedge Fund Activity: Q4 2019 in Review
47 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2019, worth a combined $23M — up 423% from $4.41M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CLSD positions and 6 closed out — a net gain of 13 holders — while 8 added to existing stakes and 10 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $434K. The largest seller was SignatureFD, cutting an estimated $176K.
- 47 institutional investors held Clearside Biomedical (CLSD) as of Q4 2019, up from 34 in Q3 2019.
- Funds reported $23M of Clearside Biomedical stock for Q4 2019, up 423% quarter-over-quarter.
- 19 funds opened new Clearside Biomedical positions in Q4 2019 and 6 closed out, a net change of +13 holders.
- The largest Clearside Biomedical buyer in Q4 2019 was Susquehanna International Group, an estimated $434K added.
- The largest Clearside Biomedical seller in Q4 2019 was SignatureFD, an estimated $176K sold.
Based on aggregated 13F filings for Q4 2019.